Postmarketing Cases of Enfortumab Vedotin-Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis

JAMA Dermatol. 2021 Oct 1;157(10):1237-1239. doi: 10.1001/jamadermatol.2021.3450.

Abstract

This case series study uses data from the FDA Adverse Event Reporting System to investigate a potential association between enfortumab vedotin treatment and Stevens-Johnson Syndrome and toxic epidermal necrolysis.

Publication types

  • Letter

MeSH terms

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Humans
  • Stevens-Johnson Syndrome* / diagnosis
  • Stevens-Johnson Syndrome* / etiology

Substances

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • enfortumab vedotin